U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act oil 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10709208
Filing Date		2004-04-21
First Named Inventor David		d Gascoyne
Art Unit		2876
Examiner Name Thier		n T. Mai
Attorney Docket Number		148527-1

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date Name of Patentee or Applicant of cited Document			Releva		Lines where		
	1	3928226		1975-1	2-23	McDonough e	tal				
	2	4127773		1978-1	1-28	West					
	3	5918960		1999-07-06 Hopwood o		Hopwood et al					
	4	6612494	B1	2003-0	9-02	Outwater					
If you wis	to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹		Publication Name of Patentee or Applicant of cited Document			Releva		Lines where ges or Relev	
	1										
If you wis	to a	d additional U.S. Public	shed Ap	plication	citation	n information p	blease click the Add	button	Add		_
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document	or v	vhere Rel	or Relevant	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

0990890

EP

2005; Date of Mailing 09.09.2005

Application Number		10709208		
Filing Date		2004-04-21		
First Named Inventor David		i Gascoyne		
Art Unit		2876		
Examiner Name Thier		T. Mai		
Attorney Docket Number		148527-1		

2000-04-05 Barmore, et al

	2	1178429	EP	A2	2002-02-06	Louis H. Liang			
	3	0171646	wo	A1	2001-09-27	Keay			
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	Add		
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials* Cite Initials* Cite (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									
	International Search Report: International Application No. PCT/US2005/013353; International Search Date 4 July								

A1

If you wish to add additional non-patent literature document citation information please click the Add button Add

FXAMINES SIGNATURE

Examiner Signature	Date Considered	
*EXAMINER: Initial if	reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a	
citation if not in confo	rmance and not considered. Include copy of this form with next communication to applicant.	

See Kinc Code of USPTO Patent Documents at year USPTO_GOV or NEPP 001.04. Ester office that issued the document, by the two-biller code (WIPO Standard S13.) "Sor Jurapence patent concurrents, the calcaded of the year of the region of the Emport and practice the search and two-for of the patent of the region of the Emport and practice the search colument.

*Kind of Gourment by the appropriate symbols as indicated on the document under WIPO Standard S11.98 if possible. *Applicant is to place a check mark there if Employ the appropriate symbols are document under WIPO Standard S11.98 if possible. *Applicant is to place a check mark there if Employ the applicant processible.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10709208		
Filing Date		2004-04-21		
First Named Inventor David		Gascoyne		
Art Unit		2876		
Examiner Name Thien Attorney Docket Number		T. Mai		
		148527-1		

CERTIFICATION STATEMENT

Please see 3	7 CFR	1.97 and	1.98 to make the appropriate selection(s):
--------------	-------	----------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Pamela J. Curbelo/	Date (YYYY-MM-DD)	2006-08-28
Name/Drint	Domoio I Curbolo	Desistration Number	2.4676

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to a patient application or patient. If you do not furnish the requested the process another examine your submission, which may visually intermediate or of redesting to a submission or the basic log process another examine; your submission, which may visually intermediate or of redesting to a submission or the submission or the submission of the submission or the submission of the submission of the submission or the submission of the submission or the submission of the submission or the submission or the submission of the submission or the submission or the submission or the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.